A 5-month, randomized, placebo-controlled trial of galantamine in AD

加兰他明 耐受性 安慰剂 不利影响 医学 内科学 随机对照试验 心理学 麻醉 痴呆 多奈哌齐 疾病 替代医学 病理
作者
Pierre N. Tariot,Paul R. Solomon,Julie Morris,Paul Kershaw,Sean Lilienfeld,Changhai Ding
出处
期刊:Neurology [Lippincott Williams & Wilkins]
卷期号:54 (12): 2269-2276 被引量:916
标识
DOI:10.1212/wnl.54.12.2269
摘要

Objectives: To evaluate further in a phase III, double blind trial the efficacy of infliximab in patients with active psoriatic arthritis (PsA), as observed in the smaller IMPACT trial. Methods: 200 patients with active PsA unresponsive to previous treatment were randomised to infusions of infliximab 5 mg/kg or placebo at weeks 0, 2, 6, 14, and 22. Patients with inadequate response entered early escape at week 16. The primary measure of clinical response was ACR20. Other measures included Psoriatic Arthritis Response Criteria (PsARC), Psoriasis Area and Severity Index (PASI), and dactylitis and enthesopathy assessments. Results: At week 14, 58% of patients receiving infliximab and 11% of those receiving placebo achieved an ACR20 response and 77% of infliximab patients and 27% of placebo patients achieved PsARC (both p<0.001). Among the 85% of patients with at least 3% body surface area psoriasis involvement at baseline, 53/83 (64%) patients receiving infliximab had at least 75% improvement in PASI compared with 2/87 (2%) patients receiving placebo at week 14 (p<0.001). These therapeutic effects were maintained through the last evaluation (week 24). Fewer infliximab patients than placebo patients had dactylitis at week 14 (18% v 30%; p = 0.025) and week 24 (12% v 34%; p<0.001). Fewer infliximab patients (22%) than placebo patients (34%) had active enthesopathy at week 14 (p = 0.016); corresponding figures at week 24 were 20% and 37% (p = 0.002). Infliximab was generally well tolerated, with a similar incidence of adverse events in each group. Conclusions: Infliximab 5 mg/kg through 24 weeks significantly improved active PsA, including dactylitis and enthesopathy, and associated psoriasis.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
doomedQL完成签到,获得积分10
1秒前
燕子完成签到 ,获得积分10
1秒前
1秒前
啦啦啦完成签到,获得积分10
1秒前
小白完成签到,获得积分10
2秒前
吴秋阳完成签到 ,获得积分10
2秒前
王老师完成签到 ,获得积分10
2秒前
skycool完成签到,获得积分10
3秒前
lujianqi发布了新的文献求助150
4秒前
晓风完成签到,获得积分0
5秒前
congyang完成签到,获得积分20
5秒前
淇淇完成签到 ,获得积分10
6秒前
平常的朝雪完成签到 ,获得积分10
6秒前
bigger.b完成签到,获得积分0
6秒前
lolo完成签到,获得积分10
6秒前
FR完成签到,获得积分10
6秒前
小芒果发布了新的文献求助10
6秒前
kobe完成签到 ,获得积分10
6秒前
5999完成签到 ,获得积分10
7秒前
6666666完成签到,获得积分10
7秒前
3475完成签到,获得积分10
7秒前
Firsterchao的应助被科研通管家采纳,获得10
7秒前
cdercder的应助被科研通管家采纳,获得10
7秒前
Hello的应助被科研通管家采纳,获得10
7秒前
吃人陈完成签到,获得积分10
7秒前
鱼鱼完成签到,获得积分10
7秒前
小二郎的应助被科研通管家采纳,获得10
7秒前
落寞万仇完成签到,获得积分10
7秒前
乐乐笑语的应助被科研通管家采纳,获得10
7秒前
小黑马完成签到,获得积分10
7秒前
桐桐的应助被科研通管家采纳,获得10
8秒前
粼望步完成签到,获得积分10
8秒前
8秒前
cdercder的应助被科研通管家采纳,获得10
8秒前
秒速五厘米完成签到,获得积分0
10秒前
称心小松鼠完成签到,获得积分10
11秒前
晨曦完成签到 ,获得积分10
11秒前
Aoia完成签到,获得积分10
11秒前
just do it完成签到,获得积分10
12秒前
自信半梦完成签到,获得积分10
12秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8180111
求助须知:如何正确求助?哪些是违规求助? 9570235
关于积分的说明 21809065
捐赠科研通 7776183
什么是DOI,文献DOI怎么找? 3433262
关于科研通互助平台的介绍 2557463
邀请新用户注册赠送积分活动 2479038